9vHPV (Nonavalent) Vaccine Policy in Indonesia

Abstract

The Human papillomavirus (HPV) vaccine is the most common sexually transmitted infection worldwide. In Indonesia, cervical cancer is the second most common cancer in women, and HPV infection is the main cause. The distribution of HPV vaccine serotypes in Indonesia according to a study by Utomo et al. showed that out of 11,224 women, the most prevalent infections were types 52, 16, 18, and 58. The nonavalent HPV vaccine consists of virus-like particles that trigger an immune response against fi ve additional high-risk HPV types (31, 33, 45, 52, and 58), in addition to the four types (6, 11, 16, and 18) protected by the quadrivalent vaccine. The vaccine works by triggering the production of antibodies that can fi ght against the targeted HPV virus, thus preventing HPV-related infections and diseases. The nonavalent HPV vaccine has the potential to accelerate the elimination of cervical cancer. The 90-70-90 strategy is a global target set by the World Health Organization (WHO) to achieve the elimination of cervical cancer by 2030. This target includes three main indicators: 90% of all women must be vaccinated against HPV, 70% of women infected with HPV must be treated, and 90% of women diagnosed with cervical cancer must receive appropriate treatment. Implementation of the 90-70-90 strategy is expected to accelerate the global elimination of cervical cancer and provide signi fi cant health bene fi ts for women worldwide.